Education
About Us
Working with TipRanks
Follow Us
Kiromic Biopharma, Inc. (KRBPQ)
:KRBPQ
KRBPQ Stock Chart & Stats
$0.04
--
Market closed
$0.04
--
Day’s Range― - ―
52-Week Range$0.03 - $1.80
Previous CloseN/A
VolumeN/A
Average Volume (3M)3.09K
Market Cap
$13.27K
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.19
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-22.86
Shares Outstanding2,653,479
10 Day Avg. Volume3,734
30 Day Avg. Volume3,091
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Kiromic Biopharma News
KRBPQ FAQ
What was Kiromic Biopharma, Inc.’s price range in the past 12 months?
Kiromic Biopharma, Inc. lowest stock price was $0.03 and its highest was $1.80 in the past 12 months.
What is Kiromic Biopharma, Inc.’s market cap?
Kiromic Biopharma, Inc.’s market cap is $13.27K.
When is Kiromic Biopharma, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Kiromic Biopharma, Inc.’s earnings last quarter?
Kiromic Biopharma, Inc. released its earnings results on May 12, 2023. The company reported -$6.17 earnings per share for the quarter, missing the consensus estimate of N/A by -$6.17.
Is Kiromic Biopharma, Inc. overvalued?
According to Wall Street analysts Kiromic Biopharma, Inc.’s price is currently Overvalued.
Does Kiromic Biopharma, Inc. pay dividends?
Kiromic Biopharma, Inc. does not currently pay dividends.
What is Kiromic Biopharma, Inc.’s EPS estimate?
Kiromic Biopharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kiromic Biopharma, Inc. have?
Kiromic Biopharma, Inc. has 2,653,479 shares outstanding.
What happened to Kiromic Biopharma, Inc.’s price movement after its last earnings report?
Kiromic Biopharma, Inc. reported an EPS of -$6.17 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.415%.
Which hedge fund is a major shareholder of Kiromic Biopharma, Inc.?
Currently, no hedge funds are holding shares in KRBPQ
Company Description
Kiromic Biopharma, Inc.
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
Technical Analysis
Scorpius Holdings
―
Salarius Pharmaceuticals
―
Processa Pharmaceuticals
―
GRI Bio
―
Onconetix
―
Ownership Overview
7.81%
Insiders
― Other Institutional Investors
92.19% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---